Source - RNS
RNS Number : 1203J
GW Pharmaceuticals PLC
07 September 2016
 

 

GW Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference

 

London, UK, 7 Sept 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference to be held at the Grand Hyatt Hotel in New York City on Wednesday, 14 September 2016 at 9:55 a.m. EDT.

 

A live audio webcast of the presentations will be available through GW's corporate website in the investor relations section from the investor's calendar of events page at www.gwpharm.com. A replay will be available soon after the live presentations.

 

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 28 countries outside the United States. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com.

 

 

Enquiries:

 

GW Pharmaceuticals plc


Stephen Schultz, VP Investor Relations (U.S.)

917 280 2424 / 401 500 6570



FTI Consulting (Media Enquiries)


Ben Atwell / Simon Conway

+44 20 3727 1000

 

FleishmanHillard (U.S. Media)


Paddi Hurley / Adam Silverstein

212 453 2382 / 917 697 9313

 

Peel Hunt LLP (UK NOMAD)


James Steel

+44 20 7418 8900



 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUGUAWBUPQGAQ

Related Charts

GW Pharmaceuticals (GWP)

0.00 (0.00%)
delayed 18:15PM